Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2019

View Archived Issues

Malaria vaccine has indirect protective effects

ActoBio Therapeutics announces IND approval for AG-017 for the treatment of celiac disease

Oral HRI activator EPB-53 improves glucose intolerance through FGF21

Experiments reveal the role of GDNF in intestinal epithelial barrier dysfunction in IBD

Study of RAC1 P29S mutation in melanoma points to target for reversing BRAF inhibitor resistance

Aerie initiates first-in-human study of AR-13503 sustained-release intravitreal Implant

First patient dosed in global phase II study of BT-11 in mild to moderate ulcerative colitis

Synlogic discontinues development of SYNB-1020 for the treatment of hyperammonemia

PI3K-alpha tested as a therapeutic target for prevention of heterotopic ossification

Novel mannosylated nanovaccines sensitize melanoma to immune checkpoint modulators

The other end of APP

Vertex Pharmaceuticals, Merck Patent disclose eIF-2-alpha kinase GCN2 inhibitors

More evidence links Schwann cells to pain

Sinovent discovers beta-lactamase inhibitors

Tau imagining agents patented by AC Immune, Life Molecular Imaging

Blastocyst-like embryonic structure grown from stem cells

ST Pharm presents new antivirals

New cyclin-dependent kinase 4/6 inhibitors identified at Beta Pharma

Phase III NEPTUNE study does not meet primary endpoint in patients with high TMB

Mersana Therapeutics initiates expansion portion of phase I trial of XMT-1536

First patient enrolled in observational study of children and adolescents with Dravet syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...